新型胰岛素类似物赖谷胰岛素  

A new human insulin analogue-glulisine

作　　者：穆殿平[1] 贺雪梅[1] 温元祥[1] 

机构地区：[1]天津市第一中心医院药剂科,天津300192

出　　处：《中国新药杂志》2007年第6期489-493,共5页Chinese Journal of New Drugs

摘　　要：赖谷胰岛素(glulisine)是一新型速效人胰岛素类似物,与正规人胰岛素(RHI)相比起效更快,作用时间更短,能模拟胰岛素的生理性分泌,用于1型或2型糖尿病的治疗,并能有效控制餐后高血糖;餐前应用对于控制餐后2 h血糖效果优于RHI,并能显著降低2型糖尿病患者的糖化血红蛋白(HbA1c)水平和并发症风险;且耐受性良好。Insulin glulisine is a rapid acting type of human insulin analogue that has a faster onset of action and shorter duration of action than regular human insulin （RHI） in patients with type 1 or 2 diabetes mellitus. It works by simulating physiosecretion of insulin, leading to effectively control prandial blood glucose levels in diabetic patients. Pre-meal insulin glulisine was also more effective than RHI at controlling 2-hour post-prandial glucose excursions in patients with type 1 or 2 diabetes. In patients with type 2 diabetes, insulin glulisine induced significantly greater reductions in HbA1c levels and 2-hour post-breakfast and post-dinner blood glucose levels and the risk of complication than RHI. Insulin glulisine was generally well tolerated by patients with type 1 or 2 diabetes and had a similar safety profile to insulin lispro or RHI.

关 键 词：胰岛素类似物 赖谷胰岛素 糖尿病 

分 类 号：R977.15[医药卫生—药品] R587.1[医药卫生—药学]